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Abstract: Osteoarthritis (OA) is a debilitating joint disorder affecting more than 240 million people.
There is no disease modifying therapeutic, and drugs that are used to alleviate OA symptoms result
in side effects. Recent research indicates that inhibition of peroxisome proliferator-activated receptor
δ (PPARδ) in cartilage may attenuate the development or progression of OA. PPARδ antagonists such
as GSK3787 exist, but would benefit from delivery to joints to avoid side effects. Described here
is the loading of GSK3787 into poly(ester amide) (PEA) particles. The particles contained 8 wt.%
drug and had mean diameters of about 600 nm. Differential scanning calorimetry indicated the
drug was in crystalline domains in the particles. Atomic force microscopy was used to measure
the Young’s moduli of individual particles as 2.8 MPa. In vitro drug release studies showed 11%
GSK3787 was released over 30 days. Studies in immature murine articular cartilage (IMAC) cells
indicated low toxicity from the drug, empty particles, and drug-loaded particles and that the particles
were not taken up by the cells. Ex vivo studies on murine joints showed that the particles could
be injected into the joint space and resided there for at least 7 days. Overall, these results indicate
that GSK3787-loaded PEA particles warrant further investigation as a delivery system for potential
OA therapy.
Keywords: osteoarthritis; drug delivery; particles; poly(ester amide); GSK3787; atomic
force microscopy

1. Introduction
Osteoarthritis (OA) is the most common joint disorder worldwide and is a leading cause of
chronic pain and disability [1,2]. More than 240 million people worldwide suffer from OA, at a
cost between 1% and 2.5% of gross domestic product in developed countries [3]. The disease is
multi-faceted, affecting numerous tissues within the joint, including cartilage, bone, and synovium.
Exercise has been demonstrated to safely reduce pain and improve physical function in OA patients [4,5].
Nonsteroidal anti-inflammatory drugs (NSAIDs) can also be used, but can lead to cardiovascular [6]
and gastrointestinal complications [7]. Next stage options include intra-articular injections of
corticosteroids [8]. Unfortunately, none of the above treatments alter the progression of the disease [9].
Polymers 2020, 12, 736; doi:10.3390/polym12040736
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Joint replacement therapy can be used for end-stage disease, but is limited by risks of infection,
the potential for implant failure, and altered biomechanics which can lead to degenerative changes in
other parts of the body [10,11]. Thus, improved treatments that are capable of slowing or halting OA
progression are urgently needed.
In an effort to develop disease modifying treatments for OA, a greater emphasis has been placed
on understanding the molecular mechanisms involved in OA [12]. A number of targets have been
identified. For example, inflammatory modulators such as interleukins, [13] or the NF-κB pathway [14]
have been identified as potential targets. Ion channels, such as TRPV1 [15] or voltage gated sodium
channels, which are associated with pain, have also been investigated [16]. Recent research showed
that activation of peroxisome proliferator activator receptor (PPAR) δ resulted in the degradation of
cartilage tissue in an explant culture model [17]. In addition, cartilage specific PPARδ knockout mice
were protected from post-traumatic OA (PTOA) following a destabilizing medial meniscus surgery.
PPARδ antagonists have been previously developed. For example, GSK3787 was shown to have high
selectivity for PPARδ [18]. However, PPARδ has important roles throughout the body, particularly in
glucose and lipid metabolism [19–21], so the systemic administration of GSK3787 to treat OA would
likely not be feasible due to the high risk of side effects.
Localized delivery of drugs into joints through intra-articular injection is recognized as a promising
approach for the administration of OA therapeutics as it allows the drug to be delivered in the
appropriate dose to the target tissue, while minimizing systemic exposure, and therefore potential side
effects [22]. However, free drugs that are injected into the joint are subject to rapid clearance by lymphatic
drainage within hours, thereby limiting their ability to achieve therapeutic effects [23]. Drug delivery
systems provide an opportunity to incorporate therapeutics into a material that can provide sustained
release into the joint [24]. A number of drug delivery systems for intra-articular injection have
been developed, including liposomes [25], particles [26–28], hydrogels [29–31], and dendrimers [32].
Particles in particular have been shown to afford prolonged release in the joint over a period of
months. For example, microparticles composed of poly(lactic-co-glycolic acid)(PLGA) encapsulating
the corticosteroid triamcinolone were recently approved by the United States Food and Drug
Administration [33].
Poly(ester amide)s (PEAs) are an alternative class of biodegradable polymers to polyesters.
They have tunable thermal and mechanical properties [34], and often undergo surface erosion rather
than bulk degradation, enabling controlled drug release and reduced concentrations of potentially
inflammatory acidic species upon degradation [35,36]. Furthermore, PEAs have been shown to be
well tolerated in joints [27,28], and in other in vitro [37,38], and in vivo [39] applications. For example,
PEAs have been used as cell scaffolds for tissue regeneration and were found to support cell adhesion
and proliferation [40,41]. They have also been explored for their ability to encapsulate and release cell
growth factors and bactericides [42,43]. PEA particles loaded with celecoxib were shown to release
the drug in response to inflammation and were well tolerated in a rat model [27]. They were also
explored for the controlled release of triamcinolone [44]. We recently reported the preparation and
study of celecoxib-loaded PEA particles and found that minor changes in PEA chemical structure led
to large differences in the release rate of the drug [28]. The particles were also well tolerated in an
ovine model. However, as noted above, the delivery of NSAIDs or corticosteroids would not lead to
disease-modifying effects, so it is of interest to develop delivery systems that will enable the study of
potential disease-modifying therapies.
Here, we describe the incorporation of the PPARδ antagonist GSK3787 into PEA particles. To the
best of our knowledge, this is the first reported delivery system for GSK3787. Like our previously
reported celecoxib-loaded PEA particles [28], the GSK3787-loaded particles were prepared through an
emulsification–evaporation method but modifications to the particle preparation procedure and drug
loading were required to successfully obtain particles. The particles were characterized by scanning
electron microscopy (SEM), dynamic light scattering (DLS), and thermal analysis, and the release
rate of GSK3787 in vitro was evaluated. Thermal analysis revealed differences in how GSK3787 was
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Figure 1.
1. Chemical structures of the poly(ester amide) (PBSe) and GSK3787.

2.2. General Methods
2.2. General Methods
Molar masses were determined by size exclusion chromatography (SEC) at a flow rate of 1 mL/min
Molar masses were determined by size exclusion chromatography (SEC) at a flow rate of 1 mL/min
in DMF with 10 mM LiBr and 1% (v/v) NEt3 at 85 ◦ C using a Waters 515 HPLC pump and Waters
in DMF with 10 mM LiBr and 1% (v/v) NEt3 at 85 °C using a Waters 515 HPLC pump and Waters
Temperature Control Module II equipped with a Wyatt Optilab T-rEX refractometer and two Plgel
Temperature Control Module II equipped with a Wyatt Optilab T-rEX refractometer and two Plgel 5 μm
5 µm mixed-D (300 mm × 7.5 mm) columns from Polymer Laboratories by Varian connected in
mixed-D (300 mm × 7.5 mm) columns from Polymer Laboratories by Varian connected in series. The
series. The calibration was performed using poly(methyl methacrylate standards) (PMMA) standards.
calibration was performed using poly(methyl methacrylate standards) (PMMA) standards. DLS was
DLS was performed with a Zetasizer Nano ZS instrument from Malvern Instruments at 24.5 ◦ C.
performed with a Zetasizer Nano ZS instrument from Malvern Instruments at 24.5 °C. The Z-average
The Z-average diameter and polydispersity index (PDI) for each type of particle were measured on
diameter and polydispersity index (PDI) for each type of particle were measured on triplicate particle
triplicate particle preparations. Differential scanning calorimetry (DSC) was performed on a Q2000
preparations. Differential scanning calorimetry (DSC) was performed on a Q2000 from TA instruments
from TA instruments (New Castle, DE, USA). The heating/cooling rate was 10 ◦ C/min from 0 to +200 ◦ C,
(New Castle, DE, USA). The heating/cooling rate was 10 °C/min from 0 to +200 °C, and the data were
and the data were obtained from the second heating cycle. Statistical analyses were performed by
obtained from the second heating cycle. Statistical analyses were performed by ANOVA tests (Microsoft
ANOVA tests (Microsoft Excel, 2016) with alpha set at 0.05, followed by a Bonferroni post-hoc analysis,
Excel, 2016) with alpha set at 0.05, followed by a Bonferroni post-hoc analysis, when applicable. Animal
work was performed in compliance with the guidelines of The Canadian Council on Animal Care
guidelines (University of Western Ontario Protocol 2019-035).
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when applicable. Animal work was performed in compliance with the guidelines of The Canadian
Council on Animal Care guidelines (University of Western Ontario Protocol 2019-035).
2.3. Preparation of GSK3787-Loaded Particles (PBSe-GSK3787)
Particles loaded with the PPARδ antagonist, denoted as PBSe-GSK3787, were prepared through
an oil-in-water emulsification evaporation method. The dispersed phase of the emulsion was made
by dissolving 400 mg of PBSe in 200 mL of a 50:50 mixture of CHCl3 :CH2 Cl2 . Then, 37.5 mg of
GSK3787 was added to the dispersed phase simultaneously and was dissolved completely by stirring.
The continuous phase was prepared by dissolving 5.0 g of PVA in 1.0 L of deionized (DI) water, in a
5 L beaker. The emulsion was formed by slowly pouring the dispersed phase into the continuous
phase, while mixing vigorously using a Waring Commercial immersion blender, set to low (~9000 rpm).
The solution was continuously mixed at 9000 rpm for an additional 2 min. The resultant emulsion was
immediately transferred to a 1 L beaker ensuring that the liquid filled the beaker entirely, before being
covered with aluminum foil, and perforated with five holes to slow the evaporation rate. The organic
solvent was evaporated under constant stirring in a fume hood for 24 h. The emulsion was then
transferred to 50 mL centrifuge tubes, which were spun at 2800 g for 10 min. Solid particles sedimented
at the bottom of centrifuge tubes, and the aqueous layer was discarded. Particles in the tubes were
resuspended in 50 mL of DI water, and were spun again for 10 min at 2800 g to wash the particles.
After removing the aqueous layer, the particles were collected by resuspending the contents of each
centrifuge tube in 5 mL of DI water. Fractions from different centrifuge tubes were combined and
frozen overnight at −20 ◦ C before being lyophilized, affording a ~60% yield of particles. Note that
higher yields can be obtained by centrifugation at higher force, but then it is more difficult to redisperse
the particles afterwards. The dried samples were kept refrigerated at 4 ◦ C until use.
2.4. Preparation of Non-Drug-Loaded Particles (PBSe-NDL)
Particles without drug were prepared by the same method as for PBSe-GSK3787 except that no
drug was added to the dispersed phase. The particles were recovered in ~60% yield.
2.5. Preparation of Dye-Labeld Particles
When required for microscopic and stereoscopic examination, particles with dyes loaded into
them were prepared by the same method as for PBSe-GSK3787, with the addition of either 5 mg of Nile
red (PBSe-GSK3787-NR particles) or 5 mg of IR-780 (PBSe-GSK3787-IR particles) into the dispersed
phase of the emulsion instead of GSK3787. The particles were recovered in ~60% yield.
2.6. Scanning Electron Microscopy
SEM was performed in the University of Western Ontario’s Nanofabrication Facility using a Zeiss
LEO 1530 instrument, operating at 2.0 kV and a working distance of 6 mm. Lyophilized samples
of particles were mounted to stubs covered in carbon tape and coated with a 10 nm layer of
Osmium, using an SPI Supplies, OC-60A plasma coater. Micrographs of the particles were taken,
and images were produced to measure the size of particles. Particles in three different images and three
representative sections (~30 × 30 µm2 ) per image were measured to calculate the average diameters
± standard deviation.
2.7. Measurement of Drug Loading and Encapsulation Efficiency
Ten milligrams of PBSe-GSK3787 particles were accurately weighed. The particles were then
completely dissolved in 1 mL of dimethyl sulfoxide (DMSO). Then, 20 µL of the DMSO was
taken and added to 980 µL of the high performance liquid chromatography (HPLC) mobile phase,
40:60 acetonitrile:DI water. Samples were filtered with 0.2 µm membrane filters prior to injection.
HPLC analysis was then performed using an instrument equipped with a Waters Separations Module
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2695, a Kinetex C18 5 µm (4.6 mm diameter × 100 mm length) column connected to a C18 guard
column, and a Photodiode Array (PDA) Detector (Waters 2998). The PDA detector was used to monitor
GSK3787 absorbance at 238 nm. An isocratic eluent method with acetonitrile and DI water (40:60)
was used with a flow rate of 1 mL/min. The retention time of GSK3787 was 2.5 min. The calibration
curve was obtained by spiking the mobile phase with known concentrations of GSK3787 to form the
following standard solutions: 100, 50, 25, 10, 5, and 1 µg/mL GSK3787. All samples were filtered
through 0.2 µm membrane filters, and 100 µL was injected using the instrument method described
above. Three different particle preparations were used to evaluate drug loading and encapsulation
efficiency, and each injection was performed in duplicate. Drug loading and encapsulation efficiency
were calculated according to Equations (1) and (2).
!
Mass o f drug encapsulated in particles
× 100
% Drug Loading =
Total mass o f particles
% Encapsulation E f f iciency =

!
Actual GSK3787 : PEA mass ratio
× 100
Theoretical GSK3787 : PEA mass ratio

(1)

(2)

2.8. Atomic Force Microscopy
Particles were resuspended in PBS, and deposited on glass coverslips, dropwise. After allowing
liquid to evaporate at ambient temperature overnight, the samples were used for AFM imaging
and mechanical testing. AFM measurements were carried out using a BioScope Catalyst AFM
(Bruker) mounted on an inverted microscope (LSM 510, Zeiss, Göttingen, Germany). For indentation
measurements, samples were immersed in water and heated to 37 ◦ C, using the BioScope II Heater
Stage and Veeco/LakeShore 331S Temperature Controller. Pyramidal silicon nitride MSCT cantilevers
(Bruker) with a nominal spring constant of 0.1 N/m were used for contact mode imaging and indentation
measurements. Determination of the spring constant of all cantilevers was carried out using the thermal
noise method [45]. Images were recorded in air at a line rate of 1 Hz. For indentation measurements,
the ‘point and shoot’ mode of the BioScope software was used. After hydration of the sample, an AFM
image of a nanoparticle was acquired. A grid of 10 × 10 points was placed on the nanoparticle surface,
and a force indentation curve was recorded at each point at a force trigger of 5 nN. At each indentation
position, the Young’s modulus was determined by fitting a Hertz model (cone indenter) to the approach
curve using AtomicJ [46]. One hundred different points on each of eight individual PBSe-GSK3787
particles and seven PBSe-NDL particles were used for measurements. Outliers from the data set were
removed using a 1.5× IQR statistical method. Moduli were recorded as the mean ± standard deviation.
2.9. In Vitro Release of GSK3787
Fifty milligrams of PBSe-GSK3787 particles were resuspended in 1 mL of pH 7.4 PBS containing
2 wt.% of polysorbate 80 (sink solution) to facilitate the dissolution of the released drug. The particle
suspension was then added into a Float-A-Lyzer dialysis cassette with a molecular weight cut-off
of 10 kDa. Free (non-encapsulated) GSK3787 (50 mg/cassette) was also studied to ensure that the
release of drug from the particles was not rate-limited by drug dissolution or transport across the
dialysis membrane. Samples were placed in sealed containers with 3 mL of sink solution. All 3 mL
of the sink solution was removed every 5 days for 30 days total and replaced with fresh solution.
The concentration of drug in the sink solution was analyzed as using the HPLC method described
above for the determination of the drug loading/encapsulation efficiency. Three replicates were studied
for each of PBSe-GSK3787 and free drug and every HPLC injection was performed in duplicate.
Release was calculated as the cumulative percentage of drug in the sink solution as compared to the
total drug in the sample and is reported as the mean ± standard deviation.
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2.10. Primary Chondrocyte Harvest and Culture
IMAC cells were harvested from 5-day-old CD-1 mouse pups, as previously described [47].
Briefly, pups were sacrificed and fixated to dissection plates. Cartilage was removed from the femoral
heads, femoral condyles, and tibial plateaus. The tissue was then subjected to 1 h (3 mg/mL) followed
by 24 h (0.5 mg/mL) incubations in Collagenase D diluted in Dulbecco’s Modified Eagles Medium
supplemented with 2 mM L-glutamine, 50 U/mL penicillin, and 0.05 mg/mL streptomycin at 37 ◦ C
under 5% CO2 . The tissue fragments were then agitated by pipetting and passed through a 50 µm
cell strainer. Cells were isolated by centrifugation for 10 min at 1300 g, allowing the formation of a
pellet. The pellet was washed in PBS buffer 2 times, and then resuspended in fresh media. Cells were
counted by combining 40 µL of the cell suspension in media with 40 µL of trypan blue, mixing by
pipetting, addition of 10 µL of the trypan blue/cell suspension to a cell counter plate, and analyses on a
Bio-Rad TC20 Automated cell counter. Cells were seeded in 96-well treatment plates at a density of
5000 cells/well, in 12-well plates at a density of 3.0 × 105 cells/well, or in 24-well plates at a density of
2.5 × 105 cells/well and were allowed to grow to confluency for 7 days, with the media being replaced
every 48 h.
2.11. Cytotoxicity of GSK3787 to IMAC Cells
GSK3787 was dissolved in DMSO at a concentration of 10 mg/mL and was added to cell culture
media to afford concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 µM. To each cell-containing
well of a 96 well plate, 110 µL of treatment media was added, and allowed to incubate with the cells
for 48 h. Cells receiving media without drug served as negative controls, and cells receiving sodium
dodecyl sulfate at a concentration of 1 mg/mL served as positive controls for cell death. The media was
then aspirated and replaced with 110 µL of media containing 5.0 mg/mL of MTT reagent, then the cells
were incubated for 4 h. The MTT containing media was aspirated and 50 µL of DMSO was added
to each well to solubilize the resulting purple crystals. The plate was then placed in a plate reader
(Tecan Infinite M1000 Pro, Perkin Elmer Corporation, Waltham, MA, USA) and the absorbance at
540 nm was measured to quantify the relative metabolic activities of the cells. Four biological replicates
were performed, as well as six technical replicates per plate.
2.12. Cytotoxicity of PBSe-GSK3787 and PBSe-NDL Particles to IMAC Cells
PBSe-GSK3787 or PBSe-NDL particles were resuspended in cell culture media to afford
concentrations of 5, 10, 25, 50, 100, 150, 250, 500, 750, and 1000 µg/mL. The suspensions were
sterilized by placing them under the UV light of the cell culture hood for 1 h. The MTT assay was then
performed as described above for GSK3787.
2.13. Brightfield Imaging of IMAC Cells Treated with PBSe-GSK3787 Particles
PBSe-GSK3787 particles were resuspended in cell media at concentrations of 0, 25, 50, 100, 150,
250, 500, 750, and 1000 µg/mL, and then sterilized under the UV light of the cell culture hood for 1 h.
Then, 2 mL of suspension was added to the cell-containing wells of a 12 well plate and incubated for
48 h. Cells were imaged after 48 h of incubation with particles under bright field mode using a Biotek
Cytation 5 microscope at 20× magnification.
2.14. Confocal Microscopy of IMAC Cells Treated with PBSe-GSK3787 Particles
PBSe-GSK3787-NR particles were resuspended in culture media at a concentration of 100 µg/mL,
then sterilized under the UV light of the cell culture hood for 1 h. Then, 1 mL of the particle containing
media was added to each cell containing well in the 24 well plate, and then the cells were incubated
for 48 h. The media was then aspirated, and the cells were washed 3 times with PBS before being
fixed with a 4 wt.% paraformaldehyde (PFA) solution for 10 min at room temperature. After washing
with PBS, 1 wt.% Triton X-100 was added and cells were incubated for 10 min at room temperature.
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Cells were washed with PBS again before adding a 1% bovine serum albumin (BSA) solution and
incubating at room temperature for 30 min. AlexaFluor 488 Phalloidin stain was added to PBS at a
concentration of 10 µg/mL, then 1 mL of the PBS containing AlexaFluor 488 was added to cells and
incubated for 10 min at room temperature. Coverslips were washed with PBS before being removed
and fixed to glass slides using Immunomount with DAPI. Slides were stored in the dark until imaging.
Confocal microscopy was performed using a Zeiss LSM 900 confocal microscope. A 3D rendering of
confocal images was created using Oxford Instruments Imaris ×64 software.
2.15. Ex Vivo Intra-Articular Injection of PBSe-GSK3787 Particles
50 mg/mL suspensions of PBSe-GSK3787-IR particles were prepared, and 5 µL was drawn up into
0.5 mL veterinary insulin syringes. Four healthy, male C57BL/6 mice of various ages were sacrificed
under CO2 . 5 µL intra-articular injections of PBSe-GSK3787-IR were performed on the medial side
of right hind limbs. After injection, the limbs were resected and cultured in tissue culture medium
containing 500 mL of α-minimum essential media (MEM), supplemented with 25 mg of ascorbic acid,
0.108 g/mL β-glycerophosphate, 1.0 mL BSA, 1.25 mL L-glutamine, and 10,000 µg/mL pen-strep [17].
Imaging was performed using a Leica M165C stereo microscope. Images were taken after 7 days
of limb culture to qualitatively assess the presence of particles in the joint, and any diffusion of the
particles through surrounding tissue.
3. Results and Discussion
3.1. Preparation and Characterization of PBSe Particles
The current work employed a PEA particle delivery system based on PBSe, which was shown in our
previous work to exhibit an acceptable host response in the joints of sheep [28]. Both GSK3787-loaded
particles (PBSe-GSK3787) and non-drug-loaded (PBSe-NDL) control particles were prepared by an
emulsification evaporation technique [48]. Initially, we investigated application of our previously
developed conditions for the preparation of celecoxib-loaded PBSe particles, which involved 2 mg/mL
of PBSe in CH2 Cl2 , 30 wt.% of celecoxib relative to PBSe, 5 mg/mL of PVA in DI water, and a 5:1 ratio
of the continuous to dispersed phase [28]. At similar drug loadings of GSK3787, and even 10–15 wt.%
of GSK3787, particles formed, but were contaminated with non-particle debris (Figure S3). It was
suspected that the drug was disrupting the interface and/or might not exhibit high compatibility with
the PEA. In contrast, clean particles were obtained at loadings of 20 mg of GSK3787 per 400 mg of
PEA, and it was possible to increase this in increments of 2.5 mg up to 37.5 mg of GSK3787 per 400 mg
of PEA (8.6 wt.% of GSK3787) while cleaning obtaining spherical particles (Figure 2A). In addition,
it was found that the formation of particles was dependent on the evaporation rate of the organic
phase of the emulsion, with a slower evaporation rate allowing for the formation of cleaner particles,
without significant debris. The evaporation rates of emulsions and their effect on resultant particles has
been previously studied, and the results of these studies agree with the assertion that the slower rate of
evaporation used herein, is more effective for particle preparation [49,50]. To slow the evaporation
rate, the dispersed phase was also changed from CH2 Cl2 to 1:1 CHCl3 :CH2 Cl2 . The evaporation rates
of these two organic solvents has been studied in the past, with CHCl3 having a slower evaporation
rate [51]. Furthermore, the dissolution of PEA and drug were faster in the solvent mixture than
in pure CH2 Cl2 . Overall, these results indicate that particle preparation parameters such as drug
content, solvent polarity, and solvent evaporation rate can be tuned to accommodate the loading of
different drugs into a given particle delivery system. It is likely that the drug chemical structure,
interfacial behavior, hydrophobicity, and compatibility with the polymer play important roles in the
particle formation process.
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were faster in the solvent mixture than in pure CH2Cl2. Overall, these results indicate that particle
preparation parameters such as drug content, solvent polarity, and solvent evaporation rate can be
tuned to accommodate the loading of different drugs into a given particle delivery system. It is likely
that
the drug chemical structure, interfacial behavior, hydrophobicity, and compatibility with8 ofthe
Polymers 2020, 12, 736
17
polymer play important roles in the particle formation process.

Figure 2.
2. Scanning
Scanning
electron
micrographs
of particles
(A) PBSe-GSK3787
andPBSe-NDL
(B) PBSe-NDL
Figure
electron
micrographs
of particles
(A) PBSe-GSK3787
and (B)
(non(non-drug-loaded)
showing
spherical
morphologies
and diameters
in solid
the solid
drug-loaded)
showing
their their
spherical
morphologies
and diameters
in the
state;state;
(C)
(C)
Representative
dynamic
light
scattering
(DLS)
diameter
distributions
by
volume
%
of
PBSe-GSK3787
Representative dynamic light scattering (DLS) diameter distributions by volume % of PBSe-GSK3787
and PBSe-NDL
PBSe-NDL particles
particles showing
showing the
the smaller
smaller diameters
diameters of
and
of the
the drug-loaded
drug-loaded particles.
particles.

Particles were first assessed for their morphology by SEM. The particles prepared using 8.6 wt.%
GSK3787 or with no drug had approximately spherical shapes, and no major surface defects were
observed (Figure 2A,B). PBSe-NDL particles had some debris as previously reported [28]. In previous
work, the debris was believed to be PVA, as evidenced by the presence of a secondary Tg present in
the DSC traces [28]. Based on SEM analysis, PBSe-GSK3787 particles had a diameter of 580 ± 290 nm,
while PBSe-NDL particles had a diameter of 870 ± 74 nm (Table 1). Due to the relatively high dispersity
of diameters for the PBSe-GSK3787 particles, their mean diameters were not significantly different
statistically from the PBSe-NDL particles. The diameters of the particles suspended in solution and
their batch-to-batch reproducibility were assessed by DLS (Figure 2C and Figure S4). The Z-average
diameters were 530 ± 54 nm (PDI 0.4 ± 0.1) for PBSe-GSK3787 and 790 ± 64 nm (PDI 0.5 ± 0.1) for
PBSe-NDL, indicating good reproducibility of the preparation method. In addition, the diameters
obtained from SEM and DLS were quite similar. PBSe-GSK3787 particles had statistically smaller
diameters than the PBSe-NDL particles based on DLS. The reduction in particle diameter and relatively
high dispersity of particle diameters within a given sample might arise from the drug having a role at
the solvent interface, as noted above. Overall, the particles are expected to be small enough to not
induce a response through mechanical irritation, but large enough to not be rapidly cleared from the
joint [52]. However, if necessary the particle size can likely be tuned in the future through tuning of
the emulsion parameters.
Table 1. Physicochemical properties of PBSe-GSK3787 and PBSe-NDL particles.
Particle
Composition

Z-Average
Diameter
(DLS) (nm)

Particle
Diameter
(SEM) (nm)

GSK3787
Loading (wt.%)

GSK3787
Encapsulation
Efficiency (%)

Young’s
Modulus (MPa)

T g (◦ C)

T m (◦ C)

PBSe-NDL
PBSe-GSK3787

790 ± 64
530 ± 54

870 ± 74
580 ± 290

8.1 ± 0.4

94.0 ± 4.8

7.0 ± 1.4
2.8 ± 1.0

34
35

187

Based on HPLC analysis (Figure S5) of dissolved particles, the drug loading of PBSe-GSK3787
particles was 8.1 ± 0.4 wt.% and the encapsulation efficiency was 94 ± 5%. The high encapsulation
efficiency can be attributed to the high hydrophobicity of GSK3787, which highly favors its partition
into the dispersed phase, and thus encapsulation into the particles. As noted above, the drug loading
of GSK3787 was lower than what was previously obtained with celecoxib [28], due to differences in the
particle preparation procedure, but this lower loading should not be a major issue. GSK3787 is known
to bind to PPARδ through covalent modification of cysteine 249 on the protein, which should lead to
high potency [18].
DSC was performed to assess the integration of drug within the particles. Both PBSe-GSK3787 and
PBSe-NDL showed similar glass transition temperatures (Tg ) of 35 and 34 ◦ C, respectively (Figure 3).
In addition, a sharp melting temperature (Tm ) was noted for the drug at 190 ◦ C, and a broad Tm was
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observed
for PBSe-GSK3787 at about 187 ◦ C. The presence of a melting transition in the particles
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In previous work, we characterized the Young’s moduli of bulk PEA and its blends with celecoxib
by tensile testing in water at 37 ◦ C [28]. However, the mechanical properties of the individual particles
are important for their application in the joint, so in the current work AFM was used to measure the
Young’s moduli of individual particles by compression with the AFM tip at 37 ◦ C in water. The data was
fit to the Hertz model (Figure 4) [53]. PBSe-GSK3787 particles had a Young’s modulus of 2.8 ± 1.0 MPa,
significantly lower than the PBSe-NDL particles, which had a Young’s modulus of 8.0 ± 1.4 MPa.
A reduction in modulus was also observed previously when celecoxib was incorporated into bulk
PBSe and was attributed to increased plasticization of the polymer by water due to the capability of
the drug to hydrogen bond to water [28]. This explanation may also apply to GSK3787 as it is also
capable of hydrogen bonding. The compressive modulus of joint articular cartilage has been reported
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indicated that drug release continued at a similar rate over at least 60 days [28]. The slow drug release was
attributed to slow particle degradation by a surface erosion mechanism, as intact particles were still
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3 months and it is ideal to have stable drug concentrations in the joint over this time period [56].
Although we did not study GSK3787 release for more than 30 days from the particles, previous work
with celecoxib-loaded PBSe particles indicated that drug release continued at a similar rate over at least
60 days [28]. The slow drug release was attributed to slow particle degradation by a surface erosion
mechanism, as intact particles were still observed by SEM at 60 days [28]. In addition, previous work
involving the analysis of PBSe film and particle degradation by SEM and SEC showed that the material
Polymers 2020,
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degradation and GSK3787 release from PBSe-GSK3787. However, it should be noted that the actual drug
release rate measured in vitro should be considered as a lower limit on the rate, as biochemical factors
such as peptidases and biomechanical compression can lead to considerably faster release of drugs from
delivery systems in joints [31].
To ensure that the release of GSK3787 from the delivery system was not rate-limited by simple
dissolution of the drug or its transport across the dialysis membrane, a 50 mg/mL suspension of free
powdered GSK3787 placed in a dialysis cassette (3 mL) was used as a control. Even at this higher drug
concentration, 60% of the free GSK3787 was released into the dialysate over 30 days, showing that the
drug release for PBSe-GSK3787 particles was not rate-limited by the dissolution of the drug or transport
across the membrane (Figure 5). The release rate of free GSK3787 appeared remarkably zero order. It is
possible that saturation of the solution with GSK3787 was reached at each time point under these
conditions. In addition, dissolution of GSK3787 would be facilitated by its incorporation into micelles
Figure 4. (A) Atomic force microscopy (AFM) image of a PBSe-GSK3787 particle showing the grid
formed
by polysorbate 80 (Figure S6) which would then transport the drug across the dialysis membrane.
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3.2. In Vitro Release of GSK3787
The release of GSK3787 was measured by placing a 50 mg/mL suspension of PBSe-GSK3787 particles
inside a dialysis cassette (1 mL) and then quantifying the concentration of drug in the external dialysate
(3 mL) over time by HPLC. The experiment was performed at 37 °C in PBS containing 2 wt.% of
polysorbate 80, to enhance the solubility of the drug in the release medium. The release medium was
changed at each time point to ensure sink conditions. PBSe-GSK3787 exhibited a slow release of drug,
with only 11% of GSK3787 released after 30 days with no burst release observed (Figure 5). The relatively
high standard deviations on the cumulative release at longer time points can likely be attributed to
challenges keeping the particles well dispersed in the dialysis cassette, as they tended to agglomerate
during the course of the release study. The slow release of GSK3787 is a desirable feature for intra-articular
drug delivery, as the clinically acceptable injection frequency is once every 3 months and it is ideal to have
stable drug concentrations in the joint over this time period [56]. Although we did not study GSK3787
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The effects of PBSe-GSK3787 and PBSe-NDL particles on IMAC cells were also evaluated using an
MTT assay. There was a trend towards higher toxicity for the PBSe-GSK3787 particles, but the metabolic
activities remained above 68% of the control even at 1000 μg/mL, the highest concentration tested (Figure
6B). There were no significant differences in metabolic activities between cells exposed to PBSe-GSK3787

Polymers 2020, 12, 736

11 of 17

micelles formed by polysorbate 80 (Figure S6) which would then transport the drug across the dialysis
membrane. This could also lead to zero order kinetics as long as a depot of undissolved drug remains.
3.3. Cytotoxicity of GSK3787, PBSe-GSK3787, and PBSe-NDL to Primary Cell Cultures
IMAC cells were used in this study as they are primary cells harvested directly 11from
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The effects of PBSe-GSK3787 and PBSe-NDL particles on IMAC cells were also evaluated using
an MTT assay. There was a trend towards higher toxicity for the PBSe-GSK3787 particles, but the
metabolic activities remained above 68% of the control even at 1000 µg/mL, the highest concentration
tested (Figure 6B). There were no significant differences in metabolic activities between cells exposed
to PBSe-GSK3787 and PBSe-NDL particles at any of the concentrations. It should be noted that at
8 wt.% drug loading, 1000 µg/mL corresponds to 80 µg/mL (~200 µM) of drug. Based on the drug
release study, only a small fraction of drug should be released during the 48 h incubation, so toxic
concentrations of released drug would not be expected in the assay. However, interactions of the
particles with the cells may lead to high local concentrations of chemical species. Therefore, we also
imaged live IMAC cells using brightfield microscopy after 48 h incubation of PBSe-GSK3787 particles
with cells. The 150 µg/mL particle-treated cells remained attached to the substrate and appeared similar
in shape to control cells that were not treated with particles (Figure 7 and Figure S7). At 1000 µg/mL,
the cells
were
remarkably
covered
particles.
It iswith
possible
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coverage
onPBSethe cells
Figure
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GSK3787 particles; (C) 1000 μg/mL of PBSe-GSK3787 particles. The particles agglomerated and adhered
to
the outsides of the cell membranes. Cells treated with 150 μg/mL of particles appeared healthy, whereas
the cells were almost completely coated with particles at 1000 μg/mL.

3.4. Confocal Microscopy of IMAC Cells Treated with PBSe-GSK3787-NR
Nile red-labeled PBSe-GSK3787 particles (PBSe-GSK3787-NR) were prepared to enable
visualization of the particles using fluorescence confocal microscopy. We first checked whether 1.25
wt.% of dye had any impact on the particle size and found that it did not (Figure S8). IMAC cells
were incubated with 100 μg/mL of PBSe-GSK3787-NR particles for 48 h, and then imaging was
performed to assess how the particles interacted with the cells and whether they were taken up by

Figure 6. Metabolic activity of immature murine articular cartilage (IMAC) cells, as measured by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 48 h after treatment with
(A) increasing concentrations of the PPARδ inhibitor, GSK 3787 and (B) PBSe-GSK3787 and PBSeNDL particles. No significant toxicity was observed for the free drug or for PBSe-NDL. However, a
trend
Polymers
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12, 736 higher toxicity was observed for PBSe-GSK3787 particles. Error bars correspond to
12 of 17
standard deviations (N = 4).
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3.4. Confocal Microscopy of IMAC Cells Treated with PBSe-GSK3787-NR
3.4. Confocal Microscopy of IMAC Cells Treated with PBSe-GSK3787-NR
Nile red-labeled PBSe-GSK3787 particles (PBSe-GSK3787-NR) were prepared to enable
Nile red-labeled PBSe-GSK3787 particles (PBSe-GSK3787-NR) were prepared to enable
visualization of the particles using fluorescence confocal microscopy. We first checked whether
visualization of the particles using fluorescence confocal microscopy. We first checked whether 1.25
1.25 wt.% of dye had any impact on the particle size and found that it did not (Figure S8). IMAC cells
wt.% of dye had any impact on the particle size and found that it did not (Figure S8). IMAC cells
were incubated with 100 µg/mL of PBSe-GSK3787-NR particles for 48 h, and then imaging was
were incubated with 100 μg/mL of PBSe-GSK3787-NR particles for 48 h, and then imaging was
performed to assess how the particles interacted with the cells and whether they were taken up by
performed to assess how the particles interacted with the cells and whether they were taken up by
the cells. The cellular actin cytoskeleton was also stained with AlexaFluor 488-Phalloidin (green) and
the cells. The cellular actin cytoskeleton was also stained with AlexaFluor 488-Phalloidin (green) and
the nuclei were stained with DAPI (Figure 8A). A 3D image rendering of the confocal images showed
the nuclei were stained with DAPI (Figure 8A). A 3D image rendering of the confocal images showed
that the2020,
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then resected and cultured in organ culture media for 7 d. The culture of joints has been determined
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previously to be a good model for the study of OA, because of its low expense, and ability of the
tissue to maintain cytokine stimulation and osmotic pressure while in culture [59]. The joints were
imaged to qualitatively assess the diffusion of particles away from the joint space and through the
surrounding tissue. Using brightfield imaging, it was observed that distribution of particles had
remained localized to the joint after 7 d, with no distinct green dye seen outside of the joint space.
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4. Conclusions
4. Conclusions
PBSe particles containing the PPARδ antagonist, GSK3787, were successfully prepared by
PBSe particles containing the PPARδ antagonist, GSK3787, were successfully prepared by
modifying our previously developed procedure. Specifically, it was important to lower the loading of
modifying our previously developed procedure. Specifically, it was important to lower the loading
drug from 30 wt.% for celecoxib to 8.6 wt.% for GSK3787 in order to achieve clean particle formation.
This requirement may arise from GSK3787 acting at the interface, as supported by the formation of
smaller particles in the presence of this drug, or due to incompatibility of the drug and PBSe, which was
suggested by thermal analysis of the particles. Relative to particles without drug, the loading of
GSK3787 into the particles lowered the Young’s modulus, bringing it closer to the natural range of
articular cartilage. The particles exhibited a slow release of GSK3787 in vitro with no burst release
observed. GSK3787 exhibited low toxicity to IMAC cells, as indicated by the MTT assay. The particles
also exhibited low toxicity, except at the highest concentrations studied (>500 µg/mL) and this lowering
of metabolic activity might be due to the high concentrations of particles localized on the cell surface,
as indicated by bright field and fluorescence confocal microscopy. Knee joint explant cultures that were
injected with particles showed that the particles remained mainly localized in the joint, even after 7 days
of injection. Therefore, this system encapsulates and releases a potent PPARδ antagonist that cannot
be delivered systemically and serves as a promising vehicle for further investigated in intra-articular
drug delivery for the treatment of OA.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4360/12/4/736/s1,
Figure S1: NMR spectrum of PBSe; Figure S2: SEC trace for PBSe; Figure S3: Scanning electron micrographs
of particles prepared with different amounts of GSK3787 added; Figure S4: DLS diameter distributions of the
particles by intensity %; Figure S5: Representative HPLC trace of GSK3787 as measured for drug loading and
encapsulation efficiency of the particles; Figure S6: DLS data for GSK3787 in the presence of polysorbate 80;
Figure S7: Zoomed brightfield microscopy images; Figure S8: DLS data for particles containing Nile red or IR-780.
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